Email: Password:
| Forgot Password
Nav_logo

A free online accredited CPD program for healthcare professionals

Metastatic Castration-Resistant Prostate Cancer: Optimizing Patient-Centric Management

1.00 Canadian Council On Continuing Education In Pharmacy (CCCEP) CEU(s) / 1.00 Ordre des pharmaciens du Québec (OPQ) CEU(s)

Program available online until: April 27, 2018

This continuing education lesson is designed primarily for pharmacists and has been accredited by the Canadian Council on Continuing Education in Pharmacy (CCCEP)
for 1.00 CEU(s).


This continuing education activity has been accredited by l'Ordre des Pharmaciens du Quebec, which will grant 1.00 CEU(s) to pharmacists who have completed it successfully.

Describe the role of Androgen Receptor Axis-Targeted (ARAT) agents

/Content/Programs/CaseStudy/ProstateCancer_mCRPC_9042/assets/images/GettyImages-498426372.jpg

With one-in-eight men diagnosed in their lifetime, prostate cancer is the most commonly diagnosed non-skin cancer in Canadian men. Testosterone and other androgens play a critical role in stimulating prostate cancer growth via androgen receptor signalling. Medical or surgical castration seeks to block androgen production or action, thereby inhibiting cancer growth.

  • Because of its permanent effects, surgical castration (bilateral orchiectomy) is rarely performed.
  • Several pharmaceutical approaches are used for androgen deprivation therapy (ADT) in advanced prostate cancer, and in high-risk disease as adjuvant to local treatment.

Planning Committee

  • Robert J. Hamilton, MD MPH FRCSC.
  • Jeffrey Habert, MD, CCFP, FCFP.
  • Ted Jablonski, MD, CCFP, FCFP.
  • André Bélanger, MD, CFPC.
  • Scott Edwards, Pharm D.
  • Carlo De Angelis, PharmD.

Learning Objectives

By the end of this course, the participant will be able to:

  1. Discuss the role of specialists, family physicians and pharmacists and the importance of communication between healthcare professionals in the optimal, patient-centric management of prostate cancer
  2. Describe the role of Androgen Receptor Axis-Targeted (ARAT) agents in treating metastatic castration resistant prostate cancer (mCRPC) and know which ARAT agents are available in Canada
  3. Identify and manage the dose-adjustments, drug-drug interactions and adverse effects of ARAT agents abiraterone acetate and enzalutamide
  4. Describe the most appropriate treatment options for different patient profiles and effectively counsel patients regarding their treatment options, adverse effects and the importance of adherence

Questions answered by our expert: Dr. Robert J. Hamilton, MD, MPH, FRCSC

  1. How would you identify castration-resistant prostate cancer?
  2. How would you describe the class of ARAT agents to a patient?
  3. What are some of the key features about abiraterone to discuss with patients?
  4. What are some best practices to optimize communication among healthcare professionals involved in a patient’s care?
  5. What are some options for a chemotherapy-naïve patient with mCRPC whose cancer has progressed?
  6. What do you feel are the most important things to discuss with the prostate cancer patient starting enzalutamide?
/Content/Programs/CaseStudy/ProstateCancer_mCRPC_9042/assets/images/Dr. Hamilton.png

mdBriefCase is the practical choice to earn your CPD Credits

Icon of multiple pages

20+ therapeutic areas

100+ programs each year.

Icon of multiple pages

Quality, accredited content

Developed by leading specialists and peer-reviewed by experts at respected institutions.

Icon of multiple pages

Online convenience

Save time and money.

Join 45,000+ of your colleagues

Create your free account today